Oppenheimer & Co. Inc. Sells 137,398 Shares of Veru Inc. (NASDAQ:VERU)

Oppenheimer & Co. Inc. cut its stake in shares of Veru Inc. (NASDAQ:VERU) by 25.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 397,942 shares of the company’s stock after selling 137,398 shares during the period. Oppenheimer & Co. Inc.’s holdings in Veru were worth $306,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Cetera Advisors LLC purchased a new stake in Veru during the 1st quarter valued at about $33,000. Gladstone Institutional Advisory LLC increased its position in shares of Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after acquiring an additional 14,500 shares in the last quarter. SG Americas Securities LLC raised its holdings in Veru by 185.9% in the 3rd quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after acquiring an additional 42,997 shares during the last quarter. Rhumbline Advisers lifted its position in Veru by 3,994.8% in the 2nd quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock valued at $96,000 after acquiring an additional 110,857 shares in the last quarter. Finally, SeaCrest Wealth Management LLC boosted its stake in Veru by 313.8% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 120,000 shares of the company’s stock valued at $101,000 after purchasing an additional 91,000 shares during the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price target on shares of Veru in a report on Tuesday, November 5th.

Veru Stock Performance

VERU opened at $0.63 on Friday. The firm’s 50 day simple moving average is $0.78 and its two-hundred day simple moving average is $0.90. The company has a market capitalization of $92.06 million, a PE ratio of -1.31 and a beta of -0.47. Veru Inc. has a 1-year low of $0.36 and a 1-year high of $1.92.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.